Zolgensma sales increase by $35M

BASEL, Switzerland — AveXis Inc.’s parent company Novartis AG (NYSE: NVS) said the soon-to-be Longmont-made genetic drug Zolgensma saw global sales rise to north of $200 million last quarter.

The company’s second-quarter report out Tuesday shows the company sold $205 million of the drug, a $35 million increase from the period prior. Novartis said the increase came partially due to three new U.S. states adding newborn screening of spinal muscular atrophy, meaning about 60% of new American children are being tested for the genetic condition. The sales growth was also driven with the approval of the drug…